Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
A relatively new class of drugscalled sodium-glucose cotransporter-2 (SGLT2) inhibitorshave proven beneficial for both diabetic and non-diabetic CKD and appear poised to become a mainstay treatment
HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters an overview
Bocheska O., Rpaa-Kozik M., Wolak N., Bra G., Kozik A., Dubin A., Aoki W., Ueda M., Mak P., Peptides , 2013 , 48 , 49
"Boehringer dual-acting obesity shot hits mark in Phase 3 trial." April 28, 2026
US$ 28.73
US$ 24.44
US$ 29.57
US$ 25.81
US$ 21.17
